Hematology and Hematological Malignancies, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Division of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
JCO Oncol Pract. 2022 Nov;18(11):e1762-e1776. doi: 10.1200/OP.21.00714. Epub 2022 Apr 8.
Evidence suggests that patients with cancer frequently use cannabis with medicinal intent and desire clinical guidance from providers. We aimed to determine whether oncology training adequately prepares fellows to discuss medical cannabis.
A national survey study was conducted from January to March 2021. A questionnaire assessing oncology fellows' practices regarding cannabis recommendations in cancer care and their knowledge of its effectiveness and risks compared with conventional care for cancer-related symptoms was developed and sent to 155 US-based oncology training programs to distribute to trainees.
Forty programs from 25 states participated; of the 462 trainees across these programs, 189 responded (response rate of 40%). Of the participants, 52% were female; 52% were White, 33% Asian, and 5% Hispanic. Fifty-seven percent reported that they discussed medical cannabis with more than five patients in the preceding year; however, only 13% felt sufficiently informed to issue cannabis-related clinical recommendations. Twenty-four percent reported having received formal training regarding medical cannabis. Oncology fellows who reported having received prior training in medical cannabis were significantly more likely to discuss cannabis with patients (risk ratio: 1.37, 95% CI 1.06 to 1.75; = .002) and feel sufficiently informed to discuss cannabis recommendations (risk ratio: 5.06; 95% CI, 2.33 to 10.99; < .001). Many viewed the botanical as a useful adjunctive therapy that was at least as effective as conventional treatments for anorexia/cachexia (72%), nausea/vomiting (45%), and pain (41%).
Most oncology trainees not only reported engaging in discussions regarding medical cannabis with patients but also considered themselves insufficiently informed to make cannabis-related clinical recommendations. The discrepancy between the frequency of cannabis inquiries/discussions at the patient level and comfort/knowledge at the trainee provider level represents an unmet curricular need with implications for both graduate medical education and patient care.
有证据表明,癌症患者经常出于医疗目的使用大麻,并希望从医疗保健提供者那里获得临床指导。我们旨在确定肿瘤学培训是否充分使研究员能够讨论医用大麻。
我们进行了一项全国性的调查研究,时间从 2021 年 1 月至 3 月。我们开发了一份调查问卷,评估肿瘤学研究员在癌症护理中推荐大麻的做法,以及他们对大麻治疗癌症相关症状的有效性和风险的了解与传统治疗相比的情况。调查问卷被发送给 155 家美国肿瘤学培训项目,由其分发给学员。
来自 25 个州的 40 个项目参与了该研究;在这些项目的 462 名学员中,有 189 名(回应率为 40%)做出了回应。参与者中,52%为女性;52%为白人,33%为亚洲人,5%为西班牙裔。57%的人报告称,他们在过去一年中与 5 名以上的患者讨论过医用大麻;然而,只有 13%的人认为自己有足够的信息来提供与大麻相关的临床建议。24%的人报告称曾接受过医用大麻方面的正式培训。报告接受过医用大麻培训的肿瘤学研究员更有可能与患者讨论大麻(风险比:1.37,95%置信区间:1.06 至 1.75;P=0.002),并认为自己有足够的信息来讨论大麻建议(风险比:5.06;95%置信区间,2.33 至 10.99;P<0.001)。许多人认为这种植物药是一种有用的辅助疗法,至少与常规治疗厌食/恶病质(72%)、恶心/呕吐(45%)和疼痛(41%)一样有效。
大多数肿瘤学研究员不仅报告与患者讨论医用大麻,而且还认为自己没有足够的信息来提供与大麻相关的临床建议。在患者层面上对大麻的咨询/讨论的频率和在受训提供者层面上的舒适度/知识之间存在差异,这表明在研究生医学教育和患者护理方面都存在未满足的课程需求。